About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Voluntary Withdrawal from OTCQX

December 3, 2018

Click here to read more

Post navigation

Receipt of R&D Tax Incentive

Phosphagenics and Mylan Agree Settlement

Related Posts

Phosphagenics Signs Term Sheet for TPM Diclofenac Gel in Asia

September 26, 2017

Phosphagenics Placement Secures A$1.37 million

January 18, 2018

Quarterly Activities Report and 4C

July 27, 2021July 27, 2021

Recent Posts

Ethics Approval for CBD Topical Osteoarthritis Study
October 21, 2021
Dosing commences for Phase I human clinical trial
October 4, 2021
Biotech Webinar
September 23, 2021

Categories

Analyst Coverage
Company Announcement
Company Report
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.